Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Citalopram
Drug ID BADD_D00475
Description Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
Indications and Usage For the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].
Marketing Status approved
ATC Code N06AB04
DrugBank ID DB00215
KEGG ID D07704
MeSH ID D015283
PubChem ID 2771
TTD Drug ID D0Y5DO
NDC Product Code 42806-020; 71335-0541; 76282-206; 80425-0093; 37662-0340; 43353-091; 54458-980; 0054-0062; 70518-2601; 63850-3616; 0456-4040; 68071-3034; 68788-7899; 70518-2228; 76282-207; 76282-629; 43353-112; 43353-208; 50090-5172; 50090-5175; 61919-390; 0378-6231; 69097-822; 69097-824; 71610-092; 37662-0341; 37662-0342; 52427-691; 65162-053; 0378-6233; 69097-823; 60429-175; 62135-540; 65162-052; 0378-6232; 70518-2553; 70518-2617; 70518-2671; 37662-0339; 37662-0343; 50090-5170; 51655-137; 60429-173; 60429-174; 61919-389; 0456-4020; 42806-021; 54458-889; 54458-981; 65162-054; 0456-4010; 76282-628; 37662-0337; 37662-0338; 42806-019; 51655-938; 71610-412; 71610-422; 76282-208; 37662-0336; 43063-063; 51655-209
UNII 0DHU5B8D6V
Synonyms Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 59729-33-8
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anhedonia19.15.02.0070.000029%Not Available
Anorgasmia19.08.01.001--
Anxiety19.06.02.0020.000551%
Apathy19.04.04.0020.000084%Not Available
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.001--Not Available
Arrhythmia supraventricular02.03.03.0010.000019%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.000019%Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Back pain15.03.04.005--
Bladder pain20.02.02.001--Not Available
Blood pressure diastolic13.14.03.021--Not Available
Blood pressure fluctuation24.06.01.002--Not Available
Blood pressure systolic13.14.03.012--Not Available
Blunted affect19.04.01.003--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.0010.000042%
Bradycardia02.03.02.0020.000038%Not Available
Bradykinesia17.01.02.0040.000019%Not Available
Breast enlargement21.05.04.001--Not Available
Breast mass21.05.04.0020.000067%Not Available
Breast pain21.05.05.003--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene